Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183222 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00183222 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 160 participants.
The verdict
NCT00183222, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence), ondansetron a serotonin 3 antagonist medication approved to treat nausea) or their combination are effective in the reduction of alcohol craving and drinking compared to placebo.
Interventions
- DRUG naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183222
The ClinicalTrials.gov registry entry for NCT00183222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days is the first listed.
NCT00183222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183222 about?
NCT00183222 is a clinical study titled "Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking". The purpose of this study is to determine whether naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence), ondansetron a serotonin 3 antagonist medication approved to treat nausea) or their combination are effective in the reduction of alcohol craving and drinking comp...
What is the current status of trial NCT00183222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2005-05. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00183222?
The interventions under investigation include: naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days (DRUG).
Who is sponsoring clinical trial NCT00183222?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.